GlassScriptPhysician profile
Hakim Morsli
NPI 1023009909
$87,207.24
in general payments reported to CMS, 2019-2025
27 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $9,974 · 2021: $15K · 2022: $20K · 2023: $5,801 · 2024: $3,962 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,249 · Food and Beverage: $2,399 · Travel and Lodging: $20.00 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,249.00 |
| Food and Beverage | $2,398.79 |
| Travel and Lodging | $20.00 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $73,155.07 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $11,488.68 | 2020-2025 | Farxiga, Wainua |
| Cvrx, INC. | $356.84 | 2022-2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $294.33 | 2023-2025 | |
| Abbott Laboratories | $246.82 | 2022-2025 | Triclip, Merlin@Home |
| Biotronik INC. | $239.65 | 2022-2025 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| Amgen INC. | $218.62 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $176.54 | 2019-2025 | |
| Pfizer INC. | $166.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $153.59 | 2022-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.44 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.41 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $74.86 | 2023-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $69.80 | 2023 | Optimizer |
| Philips North America LLC | $65.57 | 2024 | (Ck7) Extended Holter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $60.41 | 2023-2025 | Watchman Access System, Watchman Flx |
| Scpharmaceuticals INC. | $41.32 | 2025 | |
| Altathera Pharmaceuticals LLC | $38.18 | 2025 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals International, Plc | $34.94 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $33.00 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $28.14 | 2023 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $24.76 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $17.45 | 2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $14.58 | 2023 | Camzyos |
| Cardiovascular Systems INC. | $1.43 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hakim Morsli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.